01635nam 2200397Ia 450 991069884640332120090518153522.0(CKB)5470000002397402(OCoLC)325132009(EXLCZ)99547000000239740220090518d2002 ua 0enguran|||||||||txtrdacontentcrdamediacrrdacarrierGuidance for industry[electronic resource] revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) and variant Creutzfeldt-Jakob disease (vCJD) by blood and blood productsRockville, MD :U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research,[2002]i, 33 pages digital, PDF fileTitle from PDF title page (viewed on May 18, 2009)."January 2002".Includes bibliographical references (p. 27-28).Guidance for industry Creutzfeldt-Jakob diseaseUnited StatesPreventionBloodTransfusionGovernment policyUnited StatesBlood productsGovernment policyUnited StatesCreutzfeldt-Jakob diseasePrevention.BloodTransfusionGovernment policyBlood productsGovernment policyCenter for Biologics Evaluation and Research (U.S.)GPOGPOBOOK9910698846403321Guidance for industry3434577UNINA